I made a positive post on other board and Monolith attacked

New Post Public Reply Private Reply Replies (9) Message Board
petemantx
528
I made a positive post on other board and Monolith attacked me with a series of points to show how ill-advised all us longs are. Surprisingly, I got a call from a friend in a panic over it (some people just accept everything at face value even though they have been schooled many times) so I posted the attached. I only post it here since I know it will be deleted there and I wanted a copy of it available as I thought it was pretty thorough.

Your post perfectly illustrates the point I made as I feel what you posted was a large, stinking pile of compost - and I am using those words instead of what I really feel so this post doesn't get deleted for vulgarity.

1. Leo came over from a scam. No, Leo was hired into a company that was a scam and as soon as he realized everything was balls up (that doesn't just happen overnight) he left. Show me evidence that he made out financially from his time at this company. I don't think you will find any evidence of that, so why would he have been part of a scam?

2. Aruda shares were a way to funnel cash out of IPIX. No, Cellceutix made an administrative error in the beginning days in the contract they signed Aruda to and forgot to put in the clause that he was providing no design input to Kevetrin and Prurisol and so they got caught in a quasi-BS legal play and had to pay Aruda shares as if he was a co-developer of the drugs. Menon paid the shares to Aruda out of his own holding of stock, so stockholders lost $0 on this situation.

3. Leo BOD appts and gifting shares to his son immaterial as whose business is it what Leo does with his personal shares? As to the BOD appts, you had a company of about 10 people or less so are you going to bring in priced board members to do nothing? All that was happening was pre-clinical research. Bottom line, BS FUDster topics.

4. PolyMedix assets worthless. Anybody believing this should commit themself to an insane asylum. Look up PolyMedix, the founder was a genius in a number of areas, they teamed up with one of the finest medical depts in the country at U of Penn., and the architect of the Brilacidin molecule, Dr William DeGrado (attached is a link to his profile from U of Calif San Francisco) http://www.ipharminc.com/new-blog/2017/11/21/...rug-design
Dr. De Grado is one of the greatest biological chemical engineers in the world and is the principal speaker at a conference linked below and which appears on the IPIX website (go to Newsroom, Blog, then scroll down to the 11/21/2007 site)and the referenced presentation will show why he is considered so highly in his field, a portion of which he started by developing synthetic defensin protein mimetics.

To begin with, PolyM went bankrupt because they had MASSIVE debt (IPIX has none) and chose to send thru clinical trials a drug that failed and thus brought the company to BK due to financial problems. Brilacidin was not put thru any trials, the world had no clue as to its value, yet Dr. M and Leo learned of the availability of the company pipeline of developmental synthetics and Dr. M recognized the broad spectrum applications of Brilacidin. The acquisition one day will be recognized as one of the greatest "steals" in biotech history as Brilacidin has the potential to rival Humira as the highest grossing drug in the world should B prove able to perform in the many broad areas in which indications say it should be excellent. To date, it has shined in EVERY indication tested to include both antibiotic and anti-inflammatory.

Saying PolyMedix products are worthless equates with saying that the Apple IPhone was a failure and of no consequence to Apple.

5. Aborting the ABASSI Ph3 Antibiotic trial Strictly a mgt decision that preferred to advance multiple products thru trials rather than putting all of one's eggs in one basket as that was what would have been required to allot $30MM to the ABASSI Ph3. As it is, due to this shrewd decision by mgt, we have affirmed B works amazingly well in IBD (Irritable Bowel Disorders) as affirmed by the pictures that showed not only was the Ulcerative Colitis symptoms relieved but the condition was cured, B works exceeding well for Oral Mucositis and positions B in the lead position to have this $1B+ market to themselves, Prurisol is soon to release P2B top line results regarding Psoriasis and IMO we will rival the biologics in effectiveness. Consider the effectiveness along with a much lower cost basis and nearly perfect safety profile and Prurisol should become the leading Psoriasis treatment prescribed in a $10B+ market. All in all, I would say mgt should have been given an award for their decision to follow this path rather than go all-or-nothing on a P3 ABASSI trial.

Another major statement of the value of our pipeline is the fact that we know we have 20+ CDAs so obviously BP is highly aware of our pipeline and none of them want to be left out of possibly putting in an offer as the pipeline IMO can be ranked among the greatest (if not the greatest) in history with 3 blockbuster drugs spanning a wide scope of medical conditions with total revenue targets exceeding $100B. All in all, I'd say that speaks pretty damn loudly for a small startup with about 10 employees.

6. K did not work Here again, whose word should one take, yours or Dr. Menon's, the developer of Kevetrin and the project leader for 2 current Eli Lily $1B+ cancer drugs? Dr. M said he believes Kevetrin will prove effective on possibly 50% of cancers, compared it to salt or sugar in the kitchen as it can combine with everything, had its Phase 1 clinical trial for safety stopped after 3 years because they couldn't obtain any negative side effects on PHASE 4 TERMINAL PATIENTS (think how weak their systems were coming into the trial) even though the dosing had gone from 10 units to 800 units, and, the unbelievable, it showed to activate the pathway for the p53 gene, the GUARDIAN ANGEL gene, the most researched topic in medical history, the gene regarded as the Holy Grail of cancer, and they realized that with its rapid expulsion from the body (thus no systemic buildup, a great thing for cancer treatments) that they had to formulate it into a pill that could be taken many times a day and thus they are doing that now. They had already been working on the oral formulation since 2016 and just recently contracted EVONIK, a German 38K employee, 100 country, 14B Euro, drug manufacturer to mfr the B-OM sachet with Brilacidin in the powder form. Anybody think EVONIK also has the technology to make gels/foams/creams/pills/IV/etc?

Bottom line to me is that the FUDsters are so full of hooey (again, don't want vulgarity) that even though we know they are being paid to post their drivel, they should still be brought to task when all is said and done in trying to BK a company that has the potential to treat hundreds of thousands of people worldwide for a plethora of insidious conditions.

When I said in my prior post that IPIX was like an ol' dog who is about to have the fleas that infest his body killed, I was being brutally honest. Good riddance to all you ol' fleasters, I mean FUDsters.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading